New approaches to treatment of secondary hyperparathyroidism.
A large number of patients with chronic kidney disease are affected by secondary hyperparathyroidism. The related mineral metabolism abnormalities are associated with an increased relative risk of morbidity and mortality. The management of secondary hyperparathyroidism is made more complex by the fact that the disease progresses over time. Recent approaches to its management include vitamin D analogs, non-calcium/non-aluminum containing phosphate binders and calcimimetics.
Locatelli
Francesco
F
Department of Nephrology, Dialysis and Renal Transplantation, A Manzoni Hospital, Lecco, Italy. f.locatelli@ospedale.lecco.it
Limardo
Monica
M
Pontoriero
Giuseppe
G
D002614:Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069449:Cinacalcet; D018450:Disease Progression; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D009281:Naphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood; D044169:Receptors, Calcium-Sensing / Q000819:agonists / Q000378:metabolism; D016896:Treatment Outcome; D014807:Vitamin D / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D002614:Chelating Agents; D009281:Naphthalenes; D010710:Phosphates; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D000069449:Cinacalcet